Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401054 | 0.92 | PLA2G2A (0.38) | PLA2G2AABCG2KDM4ECBLBALOX5AP | |
| SCHEMBL1401180 | 0.92 | PLA2G2A (0.38) | PLA2G2AABCG2KDM4ECBLBALOX5AP | |
| SCHEMBL3779584 | 0.92 | PLA2G2A (0.38) | PLA2G2AABCG2KDM4ECBLBALOX5AP | |
| SCHEMBL5498781 | 0.83 | CBLB (0.34) | KDM4ECBLBTP53MAPT | |
| SCHEMBL5493630 | 0.83 | PNP (0.38) | CBLBTP53 | |
| SCHEMBL5502332 | 0.82 | CBLB (0.34) | KDM4ECBLBTP53MAPT | |
| SCHEMBL3780082 | 0.82 | ABCG2 (0.36) | PLA2G2AABCG2CBLB | |
| SCHEMBL3809770 | 0.81 | PLA2G2A (0.39) | PLA2G2AABCG2KDM4EALOX5APPRMT5 | |
| SCHEMBL1401053 | 0.81 | PLA2G2A (0.36) | PLA2G2ACBLB | |
| SCHEMBL3773863 | 0.81 | PLA2G2A (0.36) | PLA2G2ACBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812393-B1 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLOROQUINOLIN-2-YL) ETHENYL]PHENYL]-3-HALOPROPYL]-BENZOATE ESTER | MATRIX LAB LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | claimed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | claimed |
| EP-1812393-A2 | \"METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES” | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | claimed |
| EP-1812394-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | claimed |
| WO-2006008750-A2 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | claimed |
| WO-2006008751-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | claimed |
| EP-1812393-B1 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLOROQUINOLIN-2-YL) ETHENYL]PHENYL]-3-HALOPROPYL]-BENZOATE ESTER | MATRIX LAB LTD (IN) | 2011-12-28 | — | — | EP | disclosed |
| US-7858793-B2 | Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates | SATYANARAYANA CHAVA | 2010-12-28 | — | — | US | disclosed |
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | SATYANARAYANA CHAVA | 2008-11-06 | — | — | US | disclosed |
| EP-1812393-A2 | \"METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES” | Matrix Laboratories Ltd (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006008750-A2 | METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES | MATRIX LABORATORIES LTD (IN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275243-A1 | Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts | HTR3C, HTR3B, TPMT | PLA2G2A 3773/4885ABCG2 39/4885KDM4E 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.